WO2007046113A3 - Composition pharmaceutique renfermant un ou plusieurs alcaloides et procede - Google Patents

Composition pharmaceutique renfermant un ou plusieurs alcaloides et procede Download PDF

Info

Publication number
WO2007046113A3
WO2007046113A3 PCT/IN2006/000408 IN2006000408W WO2007046113A3 WO 2007046113 A3 WO2007046113 A3 WO 2007046113A3 IN 2006000408 W IN2006000408 W IN 2006000408W WO 2007046113 A3 WO2007046113 A3 WO 2007046113A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
inflammatory
alkaloid
active agent
pharmaceutical composition
Prior art date
Application number
PCT/IN2006/000408
Other languages
English (en)
Other versions
WO2007046113A2 (fr
Inventor
Rajesh Jain
Kour Chand Jindal
Aniruddha Datta
Original Assignee
Panacea Biotec Ltd
Rajesh Jain
Kour Chand Jindal
Aniruddha Datta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd, Rajesh Jain, Kour Chand Jindal, Aniruddha Datta filed Critical Panacea Biotec Ltd
Publication of WO2007046113A2 publication Critical patent/WO2007046113A2/fr
Publication of WO2007046113A3 publication Critical patent/WO2007046113A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Compositions pharmaceutiques antiinflammatoires, antiallergiques et/ou antiasthmatiques comprenant au moins un ou plusieurs composants alcaloïdes dérivés d'une source naturelle, semi-synthétique ou synthétique, comme principe actif, soit isolément soit en combinaison avec un ou plusieurs autres principes actifs, éventuellement avec d'autres excipients pharmaceutiquement acceptables. On décrit aussi des procédés d'élaboration et d'utilisation correspondants. De préférence, ce type de composition se présente sous la forme d'inhalateur à poudre sèche ou d'aérosol-doseur, de préférence aux fins d'administration par voie pulmonaire, nasale ou orale, et de préférence encore par inhalation, utile pour la prévention ou le traitement, notamment de troubles inflammatoires, allergiques et/ou respiratoires du type asthme et/ou maladie(s) pulmonaire(s) obstructive(s) chronique(s), ou tout autre trouble associé.
PCT/IN2006/000408 2005-10-18 2006-10-17 Composition pharmaceutique renfermant un ou plusieurs alcaloides et procede WO2007046113A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2776/DEL/2005 2005-10-18
IN2776DE2005 2005-10-18

Publications (2)

Publication Number Publication Date
WO2007046113A2 WO2007046113A2 (fr) 2007-04-26
WO2007046113A3 true WO2007046113A3 (fr) 2007-07-26

Family

ID=37890937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000408 WO2007046113A2 (fr) 2005-10-18 2006-10-17 Composition pharmaceutique renfermant un ou plusieurs alcaloides et procede

Country Status (1)

Country Link
WO (1) WO2007046113A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535641A (zh) * 2015-05-06 2017-03-22 Eid帕里(印度)有限公司 促进植物生长的生物刺激素混合物及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI504394B (zh) * 2011-04-29 2015-10-21 Ind Tech Res Inst 安托芬之製備方法
CN103408557B (zh) * 2013-08-19 2015-04-29 南京大学 一类吲哚里西啶生物碱及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3527335A1 (de) * 1985-07-31 1987-02-05 Hoechst Ag Verfahren zur mikrobiellen hydroxylierung von forskolin und seinen derivaten durch mortierella-staemme
DE4137540A1 (de) * 1991-11-14 1993-05-19 Steigerwald Arzneimittelwerk Verwendung von praeparaten der curcuma-pflanzen
WO2002066491A1 (fr) * 2001-02-15 2002-08-29 Sabinsa Corporation Acides boswelliques hydrosolubles, mode d"obtention et utilisation contre des états inflammatoires
WO2003080618A1 (fr) * 2002-03-21 2003-10-02 Council Of Scientific And Industrial Research Procede ameliore de production de vasicine
WO2005077393A1 (fr) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Preparation a base d'herbes medicinales comportant des extraits d'adhatoda, d'hedychium et de curcuma comme sirop contre la toux
EP1604990A1 (fr) * 2004-06-11 2005-12-14 National Health Research Institutes Alkaloides de Phenanthroindolizidine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3527335A1 (de) * 1985-07-31 1987-02-05 Hoechst Ag Verfahren zur mikrobiellen hydroxylierung von forskolin und seinen derivaten durch mortierella-staemme
DE4137540A1 (de) * 1991-11-14 1993-05-19 Steigerwald Arzneimittelwerk Verwendung von praeparaten der curcuma-pflanzen
WO2002066491A1 (fr) * 2001-02-15 2002-08-29 Sabinsa Corporation Acides boswelliques hydrosolubles, mode d"obtention et utilisation contre des états inflammatoires
WO2003080618A1 (fr) * 2002-03-21 2003-10-02 Council Of Scientific And Industrial Research Procede ameliore de production de vasicine
WO2005077393A1 (fr) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Preparation a base d'herbes medicinales comportant des extraits d'adhatoda, d'hedychium et de curcuma comme sirop contre la toux
EP1604990A1 (fr) * 2004-06-11 2005-12-14 National Health Research Institutes Alkaloides de Phenanthroindolizidine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AMLA V ET AL: "Pharmacokinetics of vasicine in healthy Indian volunteers.", ZHONGGUO YAO LI XUE BAO = ACTA PHARMACOLOGICA SINICA MAR 1987, vol. 8, no. 2, March 1987 (1987-03-01), pages 190 - 192, XP002431416, ISSN: 0253-9756 *
CHEN X Y ET AL: "Studies on the anti-inflammatory and analgesic effects of xuelian (saussurea involucrata maxim) X injection", CAPLUS, 2003, XP002975818 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2004, LALLA, JOGENDER K. ET AL: "Estimation of the saussurine content of root powder and a tablet formulation prepared from Saussurea lappa", XP002432442, retrieved from STN Database accession no. 2004:255886 *
GOPALAKRISHNAN C ET AL: "PHARMACOLOGICAL INVESTIGATIONS OF TYLOPHORINE, THE MAJOR ALKALOID OF TYLOPHORA INDICA", INDIAN JOURNAL OF MEDICAL RESEARCH, INDIAN COUNCIL OF MEDICAL RESEARCH, NEW DEHLI, IN, vol. 69, no. 3, March 1979 (1979-03-01), pages 513 - 520, XP008045245, ISSN: 0019-5340 *
JOURNAL OF PLANAR CHROMATOGRAPHY--MODERN TLC , 17(1), 36-39 CODEN: JPCTE5; ISSN: 0933-4173, 2004 *
KANG J S ET AL: "Costunolide inhibits interleukin-1beta expression by down-regulation of AP-1 and MAPK activity in LPS-stimulated RAW 264.7 cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 313, no. 1, 2 January 2004 (2004-01-02), pages 171 - 177, XP004479133, ISSN: 0006-291X *
LEE S-J ET AL: "Suppression of nitric oxide production in activated RAW264.7 cells by Phenanthroindolizidine alkaloids", FASEB JOURNAL (FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY), BETHESDA, US, vol. 18, no. 8,SupplS, 14 May 2004 (2004-05-14), pages C218,abstractno8243, XP009055401, ISSN: 0892-6638 *
MEHTA D R ET AL: "VASICINONE. A BRONCHODILATOR PRINCIPLE FROM ADHATODA VASICA NEES (N.O. ACANTHACEAE)", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 28, 1 February 1963 (1963-02-01), pages 445 - 448, XP000605375, ISSN: 0022-3263 *
MILLER A L: "THE ETIOLOGIES, PATHOPHYSIOLOGY AND ALTERNATIVE/COMPLEMENTARY TREATMENT OF ASTHMA", ALTERNATIVE MEDICINE REVIEW, THORNE RESEARCH INC., SANDPOINT,, US, vol. 6, no. 1, February 2001 (2001-02-01), pages 20 - 47, XP008007330, ISSN: 1089-5159 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535641A (zh) * 2015-05-06 2017-03-22 Eid帕里(印度)有限公司 促进植物生长的生物刺激素混合物及其制备方法

Also Published As

Publication number Publication date
WO2007046113A2 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
CA2550841A1 (fr) Nouvelle combinaison d'anticholinergique et de beta-mimetiques pour le traitement de maladies respiratoires
HUS1900056I1 (hu) Légzési rendellenességek kezelésére alkalmas, glikopirrolát tartalmú száraz porkészítményt tartalmazó inhaláló készülék és alkalmazása
MY143517A (en) Formoterol superfine formulation
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
AU2001295760A1 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
RU2006132040A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
WO2007109118A3 (fr) Procédés et compositions de réduction d'influx neutrophile et de traitement de dysplasie broncho-pulmonaire, de syndrome de détresse respiratoire, de maladie pulmonaire chronique, de fibrose pulmonaire, d'asthme et de maladie pulmonaire obstructive chronique
WO2009112273A3 (fr) Nouveau dosage et nouvelle formulation
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
WO2009112274A3 (fr) Nouveau dosage et nouvelle formulation
JP2013531056A5 (fr)
IL183696A0 (en) Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
JP2013542940A5 (fr)
RU2010108640A (ru) Новая комбинация терапевтических агентов
EP2682097A3 (fr) Inhalateurs de poudre sèche comprenant un support autre que le lactose
JP2015519356A5 (fr)
MY145166A (en) Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
WO2007046113A3 (fr) Composition pharmaceutique renfermant un ou plusieurs alcaloides et procede
UY28096A1 (es) Nueva formulación pulveurlenta que contiene tiotropio destinada a la inhalación
RU2008102655A (ru) Введение в дыхательные пути ингибитора тканевого фактора при воспалительных состояниях, поражающих дыхательные пути
WO2019098969A3 (fr) Compositions de poudre sèche à inhaler
RU2014144145A (ru) Фармацевтическая композиция, содержащая арформотерол и флутиказона фуроат
HRP20170192T1 (hr) Farmacetuski pripravak za inhalacijsku uporabu koji sadrži kortikoid, te kinolon ili fuzidičnu kiselinu
JP2007506768A5 (fr)
TW201605440A (zh) 阿地銨之新用途

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06809965

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06809965

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)